Analysis of Characteristics and Prognostic Factors of Full-Frequency Idiopathic Sudden Sensorineural Hearing Loss with Hyperlipidemia
Feng Qin,Mingxing Wang,Jibing Qiu,Jinbao Guo
DOI: https://doi.org/10.2147/ijgm.s487553
IF: 2.145
2024-10-29
International Journal of General Medicine
Abstract:Feng Qin, 1, 2 Mingxing Wang, 1, 2 Jibing Qiu, 1, 2 Jinbao Guo 1, 2 1 The Changzhou Clinical College of Xuzhou Medical University, Changzhou, Jiangsu, People's Republic of China; 2 Department of Otorhinolaryngology, Changzhou Third People's Hospital, Changzhou, Jiangsu, People's Republic of China Correspondence: Jinbao Guo, Department of Otorhinolaryngology, Changzhou Third People's Hospital, 300 Lanling North Road, Changzhou, Jiangsu, People's Republic of China, 213000, Email Purpose: To explore the relationship between hyperlipidemia and full-frequency idiopathic sudden sensorineural hearing loss (FFHL). Patients and Methods: A total of 145 FFHL patients admitted from September 2021 to May 2024 were analyzed. Eighty-five patients with hyperlipidemia and 60 patients with normal serum lipids statistically analyze the patient's gender, age, onset time, accompanying symptoms, and serum lipids. Measure the pure tone hearing threshold before and after treatment, and calculate the average increase in hearing threshold. Compare the correlation between various factors and prognosis. Results: The hyperlipidemia group had a higher proportion of males ( P =0.043) and vertigo ( P =0.044) compared to the control group, while other information between the two groups lacked statistical significance. Effective patients (n=44) in the hyperlipidemia group showed significant differences in vertigo ( P =0.020), age ( P =0.032), and onset ( P =0.030) compared to ineffective patients (n=41). Analysis showed that these were independent correlated factors affecting prognosis. Other indicators, including serum lipids, have no significance in predicting the prognosis of patients with hyperlipidemia and complete frequency decline in hearing loss. Conclusion: Patients with hyperlipidemia have higher rates of males and vertigo. The age, onset, and vertigo of patients with hyperlipidemia are related to prognosis, while various lipid indicators are not related to the prognosis of sudden hearing loss. Keywords: hyperlipidemia, idiopathic sudden sensorineural hearing loss, full frequency hearing loss Idiopathic sudden sensorineural hearing loss (ISSNHL) refers to unexplained sensorineural hearing loss that occurs within 72 hours. The hearing loss at two consecutive frequencies should exceed at least 20 dB. 1,2 According to the guidelines, sudden hearing loss can be divided into low-frequency hearing loss, high-frequency hearing loss, flat-frequency hearing loss, and total hearing loss. 1 Due to the belief that both are related to microcirculatory disorders, flat type, and total hearing loss type SD can be classified as full-frequency idiopathic sudden sensorineural hearing loss (FFHL), which means a type of ISSNHL with hearing level decreases at all frequencies. 1 Multiple blood test indicators are believed to be associated with ISSNHL. 3,4 Hyperlipidemia usually refers to an increase in triglycerides and/or total cholesterol in the plasma, an increase in low-density lipoprotein cholesterol, and a decrease in high-density lipoprotein cholesterol. When ≥1 of the following fasting venous plasma test indicators is met, abnormal blood lipids can be diagnosed: Total cholesterol (TC) ≥ 6.2 mmol/L; Low density lipoprotein cholesterol (LDL-C) ≥ 4.1 mmol/L; Triglycerides (TG) ≥ 2.3 mmol/L; high-density lipoprotein cholesterol (HDL-C) < 1.0 mol/L. The occurrence of this disease can be seen in people of different ages and genders, especially in the 50–69 age group, with a clear genetic predisposition. 5 Research has shown that hyperlipidemia can have an impact on the microvascular function of the inner ear, leading to ischemia and edema of the inner ear tissue, and hearing damage. 6 But there are many conflicting studies on whether hyperlipidemia has an impact on ISSNHL. 5,7 And no research has explored its impact on FFHL. This study focused on the patients with hyperlipidemia and FFHL admitted to our hospital and selected FFHL patients with normal lipid metabolism as controls to analyze potential factors affecting their prognosis. Patients diagnosed with FFHL and accompanied by hyperlipidemia were hospitalized in our department from September 2021 to May 2024 were selected as the hyperlipidemia group, while patients with FFHL and normal lipid indicators during the same period were selected as the control group. Collect general information of patients (Figure 1). All patients received an intravenous infusion of Ginaton (Ginkgo biloba extract, GBE, Chi Sheng Pharma & Biotech Co., Ltd., Hsinchu, Taiwan, China) and Fibrinolysin (Science Sun Pharmaceutical Co -Abstract Truncated-
medicine, general & internal